ERBB2 and breast carcinoma: To that end, the relative binding constants of the nano-HER2-E3, either alone or co-associated with the synthetic peptide 488-C-K3 or the eGFP-K3, were assessed on HER2+ HCC1954 and HER2- MDA-MB-231 breast cancer cells by flow cytometry (Figure 4).